Clinical Trials Arena July 26, 2024
Justine Ra

Increasing trial diversity hinges on effective communication with the patient community and optimising site dynamics.

While the topic of clinical trial diversity has been in circulation for some time, it has recently gained traction with the US Food and Drug Administration (FDA) releasing a guidance shepherding sponsors on the implementation of diversity plans.

The FDA’s call to action is meant to improve community trust in clinical trials by considering factors such as site location and community based care that could improve data quality and applicability across diverse patient populations. In a 2023 US Food and Drug Administration (FDA) drug trials snapshots summary assessing demographic representation in clinical trials for the 55 drugs approved in 2023, the Center for Drug...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Clinical Trials, FDA, Govt Agencies, Interview / Q&A, Trends
Related Articles:
Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose
Will Walgreens’ store closures disrupt its clinical trial aims?
Veeva Commercial Summit: Increased investment in medical affairs by pharma companies
Non-binding Guidance: Clinical Trial Diversity in Focus
NIH algorithm matches patients to clinical trials

Share This Article